AKEBIA THERAPEUTICS, INC.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.1M | $53.5M | $57.6M | $58.8M | $62.5M | $57.3M | $46.5M | $37.4M |
| Cost of Revenue | $10.4M | $12.3M | $12.5M | $9.4M | $9.9M | $7.6M | $20.4M | $14.2M |
| Gross Profit | $38.7M | $41.3M | $45.1M | $49.4M | $52.6M | $49.7M | $26.1M | $23.3M |
| Gross Margin | 78.8% | 77.0% | 78.2% | 84.0% | 84.1% | 86.7% | 56.2% | 62.2% |
| Operating Expenses | ||||||||
| Research & Development | $14.1M | $14.8M | $26.6M | $14.9M | $11.0M | $9.8M | $11.8M | $8.5M |
| SG&A Expense | $28.2M | $30.4M | $26.1M | $29.1M | $26.6M | $25.7M | $27.7M | $26.5M |
| Operating Income | $-6.3M | $-4.7M | $-8.6M | $4.4M | $14.1M | $13.5M | $-14.3M | $-12.5M |
| Operating Margin | -12.9% | -8.8% | -14.8% | 7.6% | 22.6% | 23.6% | -30.8% | -33.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-8.8M | $-8.9M | $-11.2M | $1.2M | $247.0K | $6.1M | $-22.8M | $-20.0M |
| Income Tax Expense | $70.0K | $126.0K | $1.0M | $615.0K | $0 | $0 | — | $0 |
| Net Income | $-8.9M | $-9.1M | $-12.2M | $540.0K | $247.0K | $6.1M | $-22.8M | $-20.0M |
| Net Margin | -18.1% | -16.9% | -21.2% | 0.9% | 0.4% | 10.7% | -49.0% | -53.5% |
| EPS (Basic) | $-0.03 | $-0.03 | $-0.05 | $0.00 | $0.00 | $0.03 | $-0.10 | $-0.10 |
| EPS (Diluted) | $-0.03 | $-0.03 | $-0.05 | $0.00 | $0.00 | $0.03 | $-0.10 | $-0.10 |
| Shares Outstanding (Basic) | 269.6M | 267.0M | 257.2M | 264.8M | 262.6M | 235.5M | 210.9M | 210.3M |
| Shares Outstanding (Diluted) | 269.6M | 267.0M | 257.2M | 274.4M | 271.1M | 241.6M | 210.9M | 210.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |